PMID- 36979992
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230331
IS  - 2227-9067 (Print)
IS  - 2227-9067 (Electronic)
IS  - 2227-9067 (Linking)
VI  - 10
IP  - 3
DP  - 2023 Feb 23
TI  - Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative 
      Review.
LID - 10.3390/children10030434 [doi]
LID - 434
AB  - Juvenile idiopathic arthritis (JIA) associated uveitis (JIA-U) is the most common 
      extra-articular manifestation of JIA, affecting 10-15% of patients, especially in 
      oligoarticular JIA where its course may be faint. Therefore, JIA-U is one of the 
      most challenging pediatric uveitis, associated with major ocular morbidity and 
      possibly leading to irreversible structural ocular damage and to 
      vision-threatening complications. Adequate management is crucial for avoiding 
      visual impairment complications. Since the introduction of biologic disease 
      modifying anti-rheumatic drugs (bDMARDS), the visual prognosis of JIA-U has 
      dramatically improved over the decades. Tumor necrosis factor-alpha (TNF-alpha) blockers 
      are the most used bDMARDs in treating JIA-U with large evidence of efficacy. 
      However, inadequate response to these agents, either due to intolerance or 
      inefficacy, may be observed, requiring a swap to other classes of 
      immunosuppressive agents, including anti-IL-6, anti-CD20, and, more recently, JAK 
      inhibitors. Tocilizumab is a humanized monoclonal antibody to the interelukin-6 
      receptor preventing IL-6 from binding to its soluble and membrane-bound 
      receptors. A growing body of literature provides promising results about the 
      efficacy of intravenous and subcutaneous tocilizumab in the treatment of JIA-U. A 
      narrative review of the literature on this topic will improve our knowledge on 
      the potential use of tocilizumab in JIA-U.
FAU - Iannone, Claudia
AU  - Iannone C
AUID- ORCID: 0009-0005-5686-0127
AD  - Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, 20122 Milan, 
      Italy.
AD  - Faculty of Medicine, University of Milan, 20122 Milan, Italy.
FAU - Marelli, Luca
AU  - Marelli L
AD  - Faculty of Medicine, University of Milan, 20122 Milan, Italy.
FAU - Costi, Stefania
AU  - Costi S
AD  - Department of Clinical Sciences and Community Health, Research Center for Adult 
      and Pediatric Rheumatic Diseases, University of Milan, 20122 Milan, Italy.
FAU - Pellico, Maria Rosa
AU  - Pellico MR
AD  - Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, 20122 Milan, 
      Italy.
AD  - Faculty of Medicine, University of Milan, 20122 Milan, Italy.
FAU - La Franca, Lamberto
AU  - La Franca L
AD  - Ophthalmology Department, Ospedale San Raffaele, University Vita-Salute, 20132 
      Milan, Italy.
FAU - Caporali, Roberto
AU  - Caporali R
AD  - Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, 20122 Milan, 
      Italy.
AD  - Department of Clinical Sciences and Community Health, Research Center for Adult 
      and Pediatric Rheumatic Diseases, University of Milan, 20122 Milan, Italy.
FAU - Miserocchi, Elisabetta
AU  - Miserocchi E
AD  - Ophthalmology Department, Ospedale San Raffaele, University Vita-Salute, 20132 
      Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230223
PL  - Switzerland
TA  - Children (Basel)
JT  - Children (Basel, Switzerland)
JID - 101648936
PMC - PMC10047268
OTO - NOTNLM
OT  - bDMARDs
OT  - juvenile idiopathic arthritis
OT  - tocilizumab
OT  - uveitis
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/30 06:00
MHDA- 2023/03/30 06:01
PMCR- 2023/02/23
CRDT- 2023/03/29 01:22
PHST- 2023/01/25 00:00 [received]
PHST- 2023/02/17 00:00 [revised]
PHST- 2023/02/21 00:00 [accepted]
PHST- 2023/03/30 06:01 [medline]
PHST- 2023/03/29 01:22 [entrez]
PHST- 2023/03/30 06:00 [pubmed]
PHST- 2023/02/23 00:00 [pmc-release]
AID - children10030434 [pii]
AID - children-10-00434 [pii]
AID - 10.3390/children10030434 [doi]
PST - epublish
SO  - Children (Basel). 2023 Feb 23;10(3):434. doi: 10.3390/children10030434.